Clinicopathology and genetic profile of synchronous multiple small adenocarcinomas: Implication for surgical treatment of an uncommon lung malignancy

Annals of Surgical Oncology

Volumn 21, Issue 8, 2014, Pages 2555-2562

  Lin, Mong Wei ^a,b   Wu, Chen Tu ^a,b   Kuo, Shuenn Wen ^a   Chang, Yih Leong ^a,b   Yang, Pan Chyr ^a,b  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GENOMIC DNA; K RAS PROTEIN; PROTEIN P53; EGFR PROTEIN, HUMAN; KRAS PROTEIN, HUMAN; ONCOPROTEIN; RAS PROTEIN; TP53 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SIZE; CANCER SURVIVAL; CLONAL VARIATION; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; LUNG LOBECTOMY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; SMOKING; SOMATIC MUTATION; SYNCHRONOUS MULTIPLE SMALL LUNG ADENOCARCINOMA; WEDGE RESECTION; ADENOCARCINOMA; CANCER STAGING; FOLLOW UP; GENETICS; LUNG NEOPLASMS; MIDDLE AGED; MORTALITY; MUTATION; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, MULTIPLE PRIMARY; PATHOLOGY; PROGNOSIS; SMALL CELL LUNG CARCINOMA; SURVIVAL RATE; VERY ELDERLY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MUTATION; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEOPLASMS, MULTIPLE PRIMARY; PROGNOSIS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SMALL CELL LUNG CARCINOMA; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84905125671     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-014-3642-5     Document Type: Article

References (30)

1. Beyreuther H. Multipicate von carcinomen bei einem fall von sog: 'Schnee- berger' lungenkrebs mit tuberculose. Virchows Arch Pathol Anat. 1924;250:230-6.
2. Ferguson MK, DeMeester TR, DesLauriers J, Little AG, Piraux M, Golomb H. Diagnosis and management of synchronous lung cancers. J Thorac Cardiovasc Surg. 1985;89:378-85. (Pubitemid 16241832)
3. Chang YL, Wu CT, Lin SC, Hsiao CF, Jou YS, Lee YC. Clonality and prognostic implications of P53 and EGFR somatic aberrations in multiple primary lung cancers. Clin Cancer Res. 2007;13:52-8.
4. Chang YL, Wu CT, Lee YC. Surgical treatment of synchronous multiple primary lung cancers: experience of 92 patients. J Thorac Cardiovasc Surg. 2007;134:630-7.
5. Nelson MA, Wymer J, Clements N Jr. Detection of K-ras gene mutations in non-neoplastic lung tissue and lung cancers. Cancer Lett. 1996;103:115-21. (Pubitemid 26125172)
6. Kozower BD, Larner JM, Detterbeck FC, Jones DR; American College of Chest Physicians. Special treatment issues in lung cancer: ACCP evidence-based clinical practice guidelines (3rd edition). Chest. 2013;143:e369-e399s.
7. Detterbeck FC, Mazzone PJ, Naidich DP, Bach PB; American College of Chest Physicians. Screening for lung cancer: ACCP evidence-based clinical practice guidelines (3rd edition). Chest. 2013;143:e78-e92s.
8. Ebright MI, Zakowski MF, Martin J, et al. Clinical pattern and pathologic stage but not histologic features predict outcome for bronchioloalveolar carcinoma. Ann Thorac Surg. 2002;74:1640-6.
9. Mun M, Kohno T. Efficacy of thoracoscopic resection for multifocal bronchioloalveolar carcinoma showing pure ground-glass opacities of 20 mm or less in diameter. J Thorac Cardiovasc Surg. 2007;134:877-82. (Pubitemid 47445616)
10. Roberts PF, Straznicka M, Lara PN, Lau DH, Follette DM, Gandara DR, et al. Resection of multifocal non-small cell lung cancer when the bronchioloalveolar subtype is involved. J Thorac Cardiovasc Surg. 2003;126:1597-602. (Pubitemid 37449193)
11. Nakata M, Sawada S, Yamashita M, Saeki H, Kurita A, Takashima S, et al. Surgical treatments for multiple primary adenocarcinoma of the lung. Ann Thorac Surg. 2004;78:1194-9. (Pubitemid 39303833)
12. Carretta A, Ciriaco P, Melloni G, et al. Surgical treatment of multiple primary adenocarcinomas of the lung. Thorac Cardiovasc Surg. 2009;57:30-4.
13. Kim HK, Choi YS, Kim J, Shim YM, Lee KS, Kim K. Management of multiple pure ground-glass opacity lesions in patients with bronchioloalveolar carcinoma. J Thorac Oncol. 2010;5:206-10.
14. Casali C, Rossi G, Marchioni A, et al. A single institution-based retrospective study of surgically treated bronchioloalveolar adenocarcinoma of the lung: clinicopathologic analysis, molecular features, and possible pitfalls in routine practice. J Thorac Oncol. 2010;5:830-6.
15. Mitsudomi T, Yatabe Y, Koshikawa T, et al. Mutations of the P53 tumor suppressor gene as clonal marker for multiple primary lung cancers. J Thorac Cardiovasc Surg. 1997;114:354-60. (Pubitemid 27400868)
16. Matsuzoa D, Hideshima T, Ohshima K, Kawahara K, Shirakusa T, Kimura A. Discrimination of double primary lung cancer from intrapulmonary metastasis by P53 gene mutation. Br J Cancer. 1999;79:1549-52. (Pubitemid 29116819)
17. Van Rens MT, Eijken EJ, Elbers JR, Lammers JW, Tilanus MG, Slootweg PJ. P53 mutation analysis for definite diagnosis of multiple primary lung carcinoma. Cancer. 2002;94:188-96. (Pubitemid 34049058)
18. Tang X, Shigematsu H, Bekele BN, et al. EGFR tyrosine kinase domain mutations are detected in histologically normal respiratory epithelium in lung cancer patients. Cancer Res. 2005;65:7568-72. (Pubitemid 41297226)
19. Travis WD, Brambilla E, Muller-Hermelink HK, et al. Pathology and genetics: tumours of the lung, pleura, thymus and heart. Lyon: IARC Press; 2004.
20. Linardou H, Dahabreh IJ, Kanaloupiti D, et al. Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systemic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol. 2008;9:962-72.
21. Sidransky D, Mikkelsen T, Schwechheimer K, Rosenblum ML, Cavanee W, Vogelstein B. Clonal expansion of P53 mutant cells is associated with brain tumour progression. Nature. 1992;355:846-7.
22. Goldstraw P. Staging manual in thoracic oncology. Denver: IASLC; 2009:85-89.
23. Yoo SB, Chung JH, Lee HJ, Lee CT, Jheon S, Sung SW. Epidermal growth factor receptor mutation and p53 overexpression during the multistage progression of small adenocarcinoma of the lung. J Thorac Oncol. 2010;5:964-9.
24. Malumbres M, Barbacid M. RAS oncogenes: the first 30 years. Nat Rev Cancer. 2003;3:459-65. (Pubitemid 37328850)
25. Bos JL. Ras oncogenes in human cancer: a review. Cancer Res. 1989;49:4682-9. (Pubitemid 19213607)
26. Sugio K, Ishida T, Yokoyama H, Inoue T, Sugimachi K, Sasazuki T. Ras gene mutations as a prognostic marker in adenocarcinoma of the human lung without lymph node metastasis. Cancer Res. 1992;52:2903-6.
27. Nakamura H, Haruki T, Adachi Y, Fujioka S, Miwa K, Taniguchi Y. Smoking affects prognosis after lung cancer surgery. Surg Today. 2008;38:227-31. (Pubitemid 351328105)
28. Sobue T, Suzuki T, Fujimoto I, Doi O, Tateishi R, Sato T. Prognostic factors for surgically treated lung adenocarcinoma patients, with special reference to smoking habit. Jpn J Cancer Res. 1991;82:33-9.
29. Okumura T, Asamura H, Suzuki K, Kondo H, Tsuchiya R. Intrapulmonary metastasis of non-small cell lung cancer: a prognostic assessment. J Thorac Cardiovasc Surg. 2001;122:24-8.
30. Martini N, Melamed MR. Multiple primary lung cancers. J Thorac Cardiovasc Surg. 1975;70:606-12.